Daily News Podcast

Brain damage, slight benefit seen in epinephrine cardiac arrest


 

Epinephrine provided a slight 30-day survival benefit, but those patients experienced more severe brain damage. Also today, nerve growth factor inhibitor shows phase-3 efficacy in osteoarthritis, National Academies issues a 5-step plan to address infections linked to opioid use disorder, and there may be beneficial class effects of SGLT2 inhibitors, including dapagliflozin. Listen to the MDedge Daily News for today’s top news.

Recommended Reading

CDC releases website for ME/CFS information
MDedge Neurology
AHRQ National Guideline Clearinghouse shutting down
MDedge Neurology
Less documentation highlights new Medicare fee proposal
MDedge Neurology
Too many antibiotics prescribed in urgent care
MDedge Neurology
Managing HIV with diabetes
MDedge Neurology
Too much to disagree on to let politics enter an office visit
MDedge Neurology
Nearly one-quarter of presurgery patients already using opioids
MDedge Neurology
Telemedicine payment expansion?
MDedge Neurology
Epinephrine for cardiac arrest: Better survival, more brain damage
MDedge Neurology
Bundle pay plan didn’t save money
MDedge Neurology